If you have been diagnosed with hypertension, you already know that even small reductions in blood pressure matter. A sustained fall of 5 mmHg in systolic blood pressure is associated with a 15–20% reduction in stroke risk and a 10% reduction in coronary heart disease risk over time. Two naturally occurring amino acids — L-arginine and L-citrulline — consistently produce reductions of that magnitude and larger in people with high blood pressure. This article explains how, what the evidence actually shows, and how to use them safely alongside your existing management plan.

Why High Blood Pressure Is So Difficult to Control

Hypertension is not a single disease but a chronic state of elevated vascular resistance. In the large majority of cases — what doctors call essential or primary hypertension — no single cause is identifiable. Instead, a combination of factors converges over years: reduced production of nitric oxide (NO) in the lining of blood vessel walls, progressive arterial stiffening, inflammation, oxidative stress, and dysregulation of the renin-angiotensin-aldosterone system that controls fluid and salt balance. Lifestyle interventions — dietary sodium reduction, regular aerobic exercise, weight management, moderating alcohol intake — can each lower systolic blood pressure by 4–8 mmHg. Medications do more, but many people experience side effects, and adherence over decades is a well-documented challenge.

This is the context in which the clinical evidence for L-arginine and L-citrulline is most relevant. These are not alternatives to prescribed medication. They are nutritional compounds with a direct mechanistic rationale in the biology of blood pressure regulation, and a now-substantial clinical evidence base in hypertensive populations specifically. Understanding both the mechanism and the evidence helps set realistic expectations — and realistic expectations are what make supplementation a sensible addition to, rather than a distraction from, a comprehensive management approach.

The Biology: Nitric Oxide and Your Blood Vessels

The inner lining of every blood vessel — the endothelium — produces nitric oxide (NO) continuously. NO is a signalling molecule that diffuses into the surrounding smooth muscle, triggering it to relax. When smooth muscle relaxes, the vessel diameter widens, resistance to blood flow falls, and blood pressure drops. This is not a pharmacological trick: it is the body’s primary mechanism for regulating vascular tone in real time. The endothelium is, in effect, a blood pressure control system that responds second-by-second to what is needed.

In people with hypertension, this system is impaired. Endothelial dysfunction — a reduced capacity of the endothelium to produce NO and respond to physiological signals — is both a cause and a consequence of chronically elevated blood pressure. Oxidative stress destroys NO before it can act. ADMA (asymmetric dimethylarginine), a naturally occurring molecule that builds up with ageing and metabolic stress, blocks the enzyme that makes NO. The result is a vicious cycle: less NO leads to higher vascular resistance, which increases the mechanical stress on vessel walls, which damages the endothelium further, which reduces NO production further.

L-arginine is the direct raw material — the substrate — that the endothelial enzyme eNOS uses to make NO. L-citrulline is arginine’s metabolic partner: taken orally, it bypasses the intestinal and liver enzymes that destroy most arginine before it reaches the bloodstream, travels to the kidneys, and is converted back into arginine efficiently and continuously. The two compounds used together provide both an immediate supply of arginine at the point of NO synthesis and a sustained reservoir that keeps arginine levels elevated for hours.

Four Ways These Compounds Lower Blood Pressure

What the Clinical Evidence Shows

The blood pressure evidence for arginine and citrulline is more robust than their reputation in mainstream health journalism suggests. When the full randomised trial base is pooled, the effect sizes are clinically meaningful — comparable to single-drug antihypertensive therapy at lower doses, and to lifestyle interventions that take months of consistent effort to achieve. Crucially, the strongest effects are found specifically in hypertensive populations, not in healthy people with normal blood pressure. This is an important distinction: these compounds appear to correct a deficit in NO-pathway function rather than simply pushing blood pressure below its natural set point.

What This Means if You Have Hypertension

A reduction of 6–10 mmHg in systolic blood pressure is not a trivial outcome. To put it in context: the DASH diet, one of the most comprehensively evidenced dietary approaches to hypertension, produces a mean SBP reduction of approximately 6–11 mmHg. A programme of regular aerobic exercise delivers approximately 5–8 mmHg. A single low-dose antihypertensive agent in the first-line class (such as a calcium channel blocker or ACE inhibitor) typically reduces SBP by 8–12 mmHg in mild-to-moderate hypertension. The blood pressure reductions seen with combined arginine and citrulline supplementation in hypertensive populations are in the same order of magnitude as these well-established first-line interventions — which is why the research is worth taking seriously.

However, there are important population-specificity findings that shape who is most likely to benefit. Virtually all of the positive blood pressure findings in this literature come from people with established endothelial dysfunction: hypertensive adults, postmenopausal women, people with overweight or type 2 diabetes, and individuals with elevated ADMA. These are exactly the people in whom NO-pathway function is most impaired, and therefore in whom restoring arginine and citrulline availability produces the largest response. Healthy, young, normotensive individuals do not show the same effects — Porto et al. (2025) found no hemodynamic effect from an acute arginine dose in healthy young men, consistent with the principle that you cannot meaningfully correct a deficit that does not exist.

If you have a confirmed hypertension diagnosis, you sit squarely in the population where this evidence applies most directly. The practical question is how to integrate these supplements sensibly within your broader management approach.

Evidence-Based Dosing for Hypertension

What the Evidence Does Not Yet Settle

Three limitations are worth understanding clearly before making a decision. First, the mechanism behind possible BP attenuation with long-term arginine use (beyond 24 days) is not yet established. The leading hypothesis is upregulation of arginase — the enzyme that breaks arginine down — as a compensatory response to sustained high doses. If this is correct, the implication is that cycling arginine (for example, 4 weeks on, 2 weeks off) may preserve the BP effect better than continuous use. No RCT has directly tested this, so it remains a hypothesis rather than a recommendation.

Second, while the evidence for combined arginine + citrulline is the strongest in the literature, no trial has tested a fixed-ratio, dual-compound protocol from the ground up in a hypertension-specific cohort with a single pre-specified primary endpoint. The combined-supplementation subgroup analysis in Luo et al. (2025) pooled heterogeneous study designs rather than a purpose-built combination trial. The effect size of −10.44 mmHg SBP is the best signal available, but it should be treated as directional rather than precisely calibrated.

Third, direct interaction studies with antihypertensive drugs are sparse. The combination of high-dose NO-pathway supplementation with phosphodiesterase-5 inhibitors, nitrate-based medications, or alpha-blockers is theoretically capable of producing additive hypotensive effects that could cause symptomatic low blood pressure. This risk is manageable with medical supervision, but it is a real consideration that cannot be dismissed.